Associations - Vanflyta (quizartinib)

FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: A1 - Approval quizartinib Sensitive : A1	quizartinib Sensitive: A1 - Approval quizartinib Sensitive : A1
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2	quizartinib + RAIN-32 Sensitive: C2 – Inclusion Criteria quizartinib + RAIN-32 Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	venetoclax + quizartinib Sensitive: C2 – Inclusion Criteria venetoclax + quizartinib Sensitive : C2	venetoclax + quizartinib Sensitive: C2 – Inclusion Criteria venetoclax + quizartinib Sensitive : C2
FLT3 mutation	Myelodysplastic Syndrome	FLT3 mutation	Myelodysplastic Syndrome	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2
CBL mutation	Myelodysplastic Syndrome	CBL mutation	Myelodysplastic Syndrome	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2	quizartinib Sensitive: C2 – Inclusion Criteria quizartinib Sensitive : C2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	gilteritinib + quizartinib + fingolimod Sensitive: C3 – Early Trials gilteritinib + quizartinib + fingolimod Sensitive : C3	gilteritinib + quizartinib + fingolimod Sensitive: C3 – Early Trials gilteritinib + quizartinib + fingolimod Sensitive : C3
FLT3 D835	Acute Myelogenous Leukemia	FLT3 D835	Acute Myelogenous Leukemia	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3
DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia	DNMT3A mutation + FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3
DNMT3A mutation	Acute Myelogenous Leukemia	DNMT3A mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3
CEBPA mutation	Acute Myelogenous Leukemia	CEBPA mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3
FLT3 D835Y	Acute Myelogenous Leukemia	FLT3 D835Y	Acute Myelogenous Leukemia	quizartinib Resistant: C3 – Early Trials quizartinib Resistant : C3	quizartinib Resistant: C3 – Early Trials quizartinib Resistant : C3
FLT3 Y842H	Acute Myelogenous Leukemia	FLT3 Y842H	Acute Myelogenous Leukemia	quizartinib Resistant: C3 – Early Trials quizartinib Resistant : C3	quizartinib Resistant: C3 – Early Trials quizartinib Resistant : C3
FLT3 F691L	Acute Myelogenous Leukemia	FLT3 F691L	Acute Myelogenous Leukemia	quizartinib Resistant: C3 – Early Trials quizartinib Resistant : C3	quizartinib Resistant: C3 – Early Trials quizartinib Resistant : C3
FLT3 D835V	Acute Myelogenous Leukemia	FLT3 D835V	Acute Myelogenous Leukemia	quizartinib Resistant: C3 – Early Trials quizartinib Resistant : C3	quizartinib Resistant: C3 – Early Trials quizartinib Resistant : C3
NPM1 mutation + DNMT3A mutation	Acute Myelogenous Leukemia	NPM1 mutation + DNMT3A mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3
TET2 mutation	Acute Myelogenous Leukemia	TET2 mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3	quizartinib Sensitive: C3 – Early Trials quizartinib Sensitive : C3
FLT3 Y842C	Acute Myelogenous Leukemia	FLT3 Y842C	Acute Myelogenous Leukemia	quizartinib Resistant: C3 – Early Trials quizartinib Resistant : C3	quizartinib Resistant: C3 – Early Trials quizartinib Resistant : C3
FLT3-ITD mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation + FLT3-TKD mutation	Acute Myelogenous Leukemia	quizartinib Resistant: C4 – Case Studies quizartinib Resistant : C4	quizartinib Resistant: C4 – Case Studies quizartinib Resistant : C4
FLT3 D835F	Acute Myelogenous Leukemia	FLT3 D835F	Acute Myelogenous Leukemia	quizartinib Resistant: C4 – Case Studies quizartinib Resistant : C4	quizartinib Resistant: C4 – Case Studies quizartinib Resistant : C4
miR-155 deletion + FLT3-ITD mutation	Acute Myelogenous Leukemia	miR-155 deletion + FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib Sensitive: D – Preclinical quizartinib Sensitive : D	quizartinib Sensitive: D – Preclinical quizartinib Sensitive : D
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	quizartinib + IACS-010759 Sensitive: D – Preclinical quizartinib + IACS-010759 Sensitive : D	quizartinib + IACS-010759 Sensitive: D – Preclinical quizartinib + IACS-010759 Sensitive : D
FLT3-ITD mutation + MLL rearrangement	Acute Myelogenous Leukemia	FLT3-ITD mutation + MLL rearrangement	Acute Myelogenous Leukemia	quizartinib + MI-503 Sensitive: D – Preclinical quizartinib + MI-503 Sensitive : D	quizartinib + MI-503 Sensitive: D – Preclinical quizartinib + MI-503 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib + PLX51107 Sensitive: D – Preclinical quizartinib + PLX51107 Sensitive : D	quizartinib + PLX51107 Sensitive: D – Preclinical quizartinib + PLX51107 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib + LY2510924 Sensitive: D – Preclinical quizartinib + LY2510924 Sensitive : D	quizartinib + LY2510924 Sensitive: D – Preclinical quizartinib + LY2510924 Sensitive : D
FLT3 N676K	Acute Myelogenous Leukemia	FLT3 N676K	Acute Myelogenous Leukemia	quizartinib Resistant: D – Preclinical quizartinib Resistant : D	quizartinib Resistant: D – Preclinical quizartinib Resistant : D
FLT3 N676D + FLT3 Y842C	Acute Myelogenous Leukemia	FLT3 N676D + FLT3 Y842C	Acute Myelogenous Leukemia	quizartinib Resistant: D – Preclinical quizartinib Resistant : D	quizartinib Resistant: D – Preclinical quizartinib Resistant : D
FLT3 D698N	Acute Myelogenous Leukemia	FLT3 D698N	Acute Myelogenous Leukemia	quizartinib Sensitive: D – Preclinical quizartinib Sensitive : D	quizartinib Sensitive: D – Preclinical quizartinib Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib + Lys05 Sensitive: D – Preclinical quizartinib + Lys05 Sensitive : D	quizartinib + Lys05 Sensitive: D – Preclinical quizartinib + Lys05 Sensitive : D
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	quizartinib + IMGN779 Sensitive: D – Preclinical quizartinib + IMGN779 Sensitive : D	quizartinib + IMGN779 Sensitive: D – Preclinical quizartinib + IMGN779 Sensitive : D

Vanflyta (quizartinib)

Associations
(40)

Associations
(40)

Vanflyta (quizartinib)

Associations(40)

Associations(40)

Associations
(40)

Associations
(40)